Jefferies Sees No Read-Through to The Medicines Company (MDCO) PCSK9 from Alnylam Setback

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. GOOGL
10. S

Go back to Jefferies Sees No Read-Through to The Medicines Company (MDCO) PCSK9 from Alnylam Setback

The Medicines Company Provides Progress Update on Ongoing ORION-1 Study of PCSK9si

October 5, 2016 4:35 PM EDT

Results from ORION-1 interim analysis with Day 90 follow-up will be presented in Late-Breaking Clinical Trial Session at American Heart Association (AHA) meeting on November 15, 2016

The Company anticipates that top-line data from Day 180 follow-up for up to 200 patients will also be presented at the Late-Breaking Clinical Trial Session

Based on review of safety data by the Independent Data Monitoring Committee through August 26, 2016 (unblinded) and the Company through September 29, 2016 (blinded), no material safety issue and, in particular, no drug-related neuropathy, elevation of liver enzymes or changes in renal function, has been... More